Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Quadrivalent HPV vaccine

Phase 2Vaccine

NNational Institute of Allergy and Infectious Diseases (NIAID)

Quadrivalent HPV vaccine is one of 129 biologic programs targeting Cervical Cancer. It is currently in Phase 2.

4

Indications

13

Total Trials

1

Active Trials

128

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical CancerActive, not recruiting

InfluenzaActive, not recruiting

PapillomaActive, not recruiting

MeningitisActive, not recruiting

Cervical CancerPhase 2

Active, not recruiting

InfluenzaPhase 2

Active, not recruiting

PapillomaPhase 2

Active, not recruiting

MeningitisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Quadrivalent HPV vaccine

NNational Institute of Allergy and Infectious Diseases (NIAID)

Fluzone

Crestor

Trexall

Alnylam Pharmaceuticals

Avigan

AAppili Therapeutics Inc.

Antihistamine

Arrowhead Pharmaceuticals

Focetria

CChiltern Pesquisa Clinica Ltda

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

PD-1/PD-L1 Inhibitors

CChuangzhen Chen

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Post-ApprovalNot yet recruiting

Quadrivalent HPV Vaccine

NCT07256912

Clinical

Trials by Indication[1]

Papilloma3 trials

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00604175·319 enrolled

Immune Memory After Papillomavirus Vaccination

Completed·EEmory University··NCT01505049·203 enrolled

Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts

Completed·UUniversity of Pretoria·Phase 3·NCT02750202·52 enrolled

Quadrivalent HPV Vaccine2 trials

A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia

Not yet recruiting·IInternational Agency for Research on Cancer·Phase 4·NCT07256912·1,266 enrolled

Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT01461096·575 enrolled

Influenza2 trials

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03058692·120 enrolled

A Phase 1, Comparator-Controlled, Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05945485·50 enrolled

Meningitis1 trial

Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00459316·384 enrolled

Pediatric1 trial

H3N2 M2SR in Pediatric Population

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03553940·43 enrolled

4 more indications

AIN1 trial

ICI-VPH: Impact of HPV Immunisation Schedules Against HPV

Completed·—·Phase 3·NCT02009800·3,364 enrolled

Cervical Cancer1 trial

Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer

Unknown status·BBuhai Wang·Phase 2·NCT04096911·20 enrolled

Immunogenicity1 trial

Immunogenicity of HPV Vaccine in Immunosuppressed Children

Completed·TThe University of New South Wales·Phase 3·NCT02263703·55 enrolled

Unspecified1 trial

Flublok or Fluzone With Advax-CpG55.2 or AF03

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03945825·241 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Quadrivalent HPV vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Quadrivalent HPV vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Quadrivalent HPV vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 2[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Related News